Barnes Akathisia Rating Scale (BARS)
|
|
- Pamela Day
- 5 years ago
- Views:
Transcription
1 Barnes Akathisia Rating Scale () Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaire Sub-team Notes to Readers This supplement is intended to be used with other CDISC User Guides for specific Therapeutic/Disease Areas and follows the CDISC Study Data Tabulation Model Implementation Guide for Human Clinical trials. Revision History Date Version Summary of Changes Barnes Akathisia Rating Scale () Draft 2013 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 1
2 1 Introduction This document describes the CDISC implementation of the Barnes Akathisia Rating Scale () questionnaire, a standard questionnaire that is typically used in clinical trials to provide an assessment of akathisia. The questionnaire preceded the CDISC CDASH CRF standards and based on its public domain status cannot be modified to CDASH standards. The representation of data collected for this questionnaire is based on the Study Data Tabulation Model Implementation Guide (SDTMIG) QS domain model, which can be found at the CDISC website at: ( These specific implementation details for this questionnaire are meant to be used in conjunction with the SDTMIG. All questionnaire documentation can be found on the CDISC web site at: ( The CDISC Intellectual Property Policy can be found on the CDISC web site at: ( 1.1 Representations and Warranties, Limitations of Liability, and Disclaimers This document is a supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials and is covered under Appendix F of that document, which describes representations, warranties, limitations of liability, and disclaimers. Please see Appendix F of the SDTMIG for a complete version of this material. 2 Copyright Status This instrument is in the public domain. CDISC has included the Barnes Akathisia Rating Scale () as part of CDISC Data Standards. Hence, CDISC developed QSTESTCD and QSTEST for each question based on the actual question text on the questionnaire. There may be many versions of this questionnaire in the public domain. CDISC has chosen to use this version as the data standard. The CDISC documentation of this instrument consists of: (1) controlled terminology, (2) standard database structure with examples, and (3) case report forms annotated with the CDISC SDTMIG submission values. Note: CDISC controlled terminology is maintained by NCI EVS. The most recent version should be accessed through the CDISC website. ( CDISC has developed this documentation at no cost to users of the instrument. The reference for this questionnaire is: Barnes Akathisia Rating Scale () (Barnes TR: A Rating Scale for Drug-Induced Akathisia. British Journal of Psychiatry 154: , 1989) Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 2
3 3 The QS Domain Model 3.1 Assumptions for Questionnaire Domain Model All assumptions and business rules described in the SDTMIG QS domain are applicable to this supplement. Additional assumptions specific to the Barnes Akathisia Rating Scale are listed below. Barnes Akathisia Rating Scale (): is a multiple-choice questionnaire that clinicians may use to provide an assessment of akathisia. Akathisia is defined by as a state of motor restlessness, sometimes produced by neuroleptic medication that ranges from a feeling of inner distress to an inability to sit still. 1. The investigator is instructed to observe the subject while standing and while sitting, at least two minutes each. There are four areas where the subject is to be evaluated, one of these is objective, two are subjective, and the final is a global assessment. 2. Six of the textual assessments, one of the objective and five of the global, are greater than the 200 characters limit currently mandated by the FDA, and hence, CDISC. To accommodate these in QSORRES the QS subteam has decided to shorten the responses to accommodate the character limit. The original and shortened values are summarized in Section Because the four minutes that the investigator must observe the subject is a minimum observation period, and not the actual evaluation interval, coupled with the fact that the investigator may use additional observations from other situations, there is not a value for the evaluation interval (QSEVLINT). 4. For, the evaluator is usually defined as INVESTIGATOR. Additional identifying information to further distinguish the rater in QSEVAL should be stored in QSEVALID. An example is rater initials. 5. Terminology: a. QSCAT, QSTESTCD and QSTEST are approved CDISC controlled terminology. b. A full list of value sets for qualifier, timing, result and unit fields is provided in Section 4: SDTM Mapping Strategy Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 3
4 3.2 Example for Barnes Akathisia Rating Scale () QS Domain Model The example below shows the terminology used to implement the questionnaire in the QS domain. This example shows the data for four subjects collected at one visit for a questionnaire. The example uses CDISC controlled terminology for QSTESTCD, QSTEST, and QSCAT. Rows 1-16 represent the questions from the form. All original results are represented with preferred terminology in QSORRES. This result is then standardized into its numeric equivalent in the character field of QSSTRESC, and this value is then transferred to the QSSTRESN field, in numeric format. Rows 4, 8, 12, 13, and 16 had QSORRES values that needed to be shortened in order to meet the 200 character SAS transport file V5 restriction. QS.XPT ROW STUDYID DOMAIN USUBJID QSSEQ QSTESTCD QSTEST QSCAT QSORRES QSSTRESC 1 STUDY001 QS Objective 2 STUDY001 QS STUDY001 QS Awareness Distress NORMAL, OCCASIONAL FIDGETY MOVEMENTS OF THE LIMBS NON-SPECIFIC SENSE OF INNER RESTLESSNESS 1 MODERATE STUDY001 QS Global Clinical Assessment MILD AKATHISIA. AWARE OF RESTLESSNESS IN THE LEGS AND/OR INNER RESTLESSNESS WORSE WHEN REQUIRED TO STAND STILL. FIDGETY MOVEMENTS, BUT RESTLESS MOVEMENTS NOT NECESSARILY OBSERVED. LITTLE/NO DISTRESS. 2 5 STUDY001 QS Objective PATIENT IS CONSTANTLY ENGAGED IN CHARACTERISTIC RESTLESS MOVEMENTS, AND/OR HAS THE INABILITY TO REMAIN SEATED OR STANDING WITHOUT WALKING OR PACING, DURING THE TIME OBSERVED 3 6 STUDY001 QS STUDY001 QS Awareness Distress AWARENESS OF INTENSE COMPULSION TO MOVE MOST OF THE TIME AND/OR REPORTS STRONG DESIRE TO WALK OR PACE MOST OF THE TIME MODERATE Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 4
5 ROW STUDYID DOMAIN USUBJID QSSEQ QSTESTCD QSTEST QSCAT QSORRES QSSTRESC 8 STUDY001 QS Global Clinical Assessment SEVERE AKATHISIA. A STRONG COMPULSION TO PACE UP AND DOWN MOST OF THE TIME. UNABLE TO SIT OR LIE DOWN FOR MORE THAN A FEW MINUTES. CONSTANT RESTLESSNESS ASSOCIATED WITH INTENSE DISTRESS AND INSOMNIA. 5 9 STUDY001 QS Objective OBSERVED PHENOMENA, AS DESCRIBED IN (1) ABOVE, WHICH ARE PRESENT FOR AT LEAST HALF THE OBSERVATION PERIOD 2 10 STUDY001 QS Awareness THE PATIENT IS AWARE OF AN INABILITY TO KEEP THE LEGS STILL, OR A DESIRE TO MOVE THE LEGS, AND/OR COMPLAINS OF INNER RESTLESSNESS AGGRAVATED SPECIFICALLY BY BEING REQUIRED TO STAND STILL 2 11 STUDY001 QS Distress MILD 1 12 STUDY001 QS Global Clinical Assessment MODERATE AKATHISIA. AWAREOF RESTLESSNESS AS DESCRIBED FOR MILD AKATHISIA ABOVE, COMBINED WITH CHARACTERISTIC RESTLESS MOVEMENTS SUCH AS ROCKING FROM FOOT TO FOOT WHEN STANDING. CONDITION DISTRESSING 3 13 STUDY001 QS Objective RESTLESS MOVEMENTS: SHUFFLING OR TRAMPING MOVEMENTS. SWINGING OF ONE LEG WHILE SITTING, AND/OR ROCKING FROM FOOT TO FOOT OR WALKING ON THE SPOT WHEN STANDING, PRESENT FOR LESS THAN HALF THE TIME 1 14 STUDY001 QS STUDY001 QS Awareness Distress NON-SPECIFIC SENSE OF INNER RESTLESSNESS 1 NO DISTRESS 0 16 STUDY001 QS Global Clinical Assessment ABSENT. NO EVIDENCE OF AWARENESS OF RESTLESSNESS. MOVEMENTS OF AKATHISIA IN THE ABSENCE OF INNER RESTLESSNESS OR COMPULSIVE DESIRE TO MOVE THE LEGS SHOULD BE CLASSIFIED AS PSEUDOAKATHISIA Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 5
6 ROW QSSTRESN QSBLFL QSEVAL VISITNUM QSDTC 1 0 Y INVESTIGATOR Y INVESTIGATOR Y INVESTIGATOR Y INVESTIGATOR Y INVESTIGATOR Y INVESTIGATOR Y INVESTIGATOR Y INVESTIGATOR Y INVESTIGATOR Y INVESTIGATOR Y INVESTIGATOR Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 6
7 ROW QSSTRESN QSBLFL QSEVAL VISITNUM QSDTC 12 3 Y INVESTIGATOR Y INVESTIGATOR Y INVESTIGATOR Y INVESTIGATOR Y INVESTIGATOR Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 7
8 CDISC SDTM Questionnaire Supplement (Version 0.1) 4 SDTM Mapping Strategy specific mapping strategy: This section is used for reference with the annotated CRF for further details on the CRF data capture and to understand the alignment of the questionnaire to the SDTM QS domain. It also provides guidance on how the result variables (QSORRES, QSSTRESC, and QSSTRESN) should be populated for the questionnaire. QSTESTCD=0101 QSTEST= 01-Objective QSORRES QSSTRESC QSSTRESN NORMAL, OCCASIONAL FIDGETY MOVEMENTS OF THE LIMBS 0 0 RESTLESS MOVEMENTS: SHUFFLING OR TRAMPING MOVEMENTS. SWINGING OF ONE LEG WHILE SITTING, AND/OR ROCKING FROM FOOT TO FOOT OR WALKING ON THE SPOT WHEN STANDING, PRESENT FOR LESS THAN HALF THE TIME OBSERVED PHENOMENA, AS DESCRIBED IN (1) ABOVE, WHICH ARE PRESENT FOR AT LEAST HALF THE OBSERVATION PERIOD PATIENT IS CONSTANTLY ENGAGED IN CHARACTERISTIC RESTLESS MOVEMENTS, AND/OR HAS THE INABILITY TO REMAIN SEATED OR STANDING WITHOUT WALKING OR PACING, DURING THE TIME OBSERVED QSTESTCD=0102 QSTEST= Awareness QSORRES QSSTRESC QSSTRESN ABSENCE OF INNER RESTLESSNESS 0 0 NON-SPECIFIC SENSE OF INNER RESTLESSNESS 1 1 THE PATIENT IS AWARE OF AN INABILITY TO KEEP THE LEGS STILL, OR A DESIRE TO MOVE THE LEGS, AND/OR COMPLAINS OF INNER RESTLESSNESS AGGRAVATED SPECIFICALLY BY BEING REQUIRED TO STAND STILL AWARENESS OF INTENSE COMPULSION TO MOVE MOST OF THE TIME AND/OR REPORTS STRONG DESIRE TO WALK OR PACE MOST OF THE TIME Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 8
9 CDISC SDTM Questionnaire Supplement (Version 0.1) QSTESTCD=0103 QSTEST= Distress QSORRES QSSTRESC QSSTRESN NO DISTRESS 0 0 MILD 1 1 MODERATE 2 2 SEVERE 3 3 QSTESTCD=0104 QSTEST= 01-Global Clinical Assessment QSORRES QSSTRESC QSSTRESN ABSENT. NO EVIDENCE OF AWARENESS OF RESTLESSNESS. MOVEMENTS OF AKATHISIA IN THE ABSENCE OF INNER RESTLESSNESS OR COMPULSIVE DESIRE TO MOVE THE LEGS SHOULD BE CLASSIFIED AS PSEUDOAKATHISIA 0 0 QUESTIONABLE. NON-SPECIFIC INNER TENSION AND FIDGETY MOVEMENTS 1 1 MILD AKATHISIA. AWARE OF RESTLESSNESS IN THE LEGS AND/OR INNER RESTLESSNESS WORSE WHEN REQUIRED TO STAND STILL. FIDGETY MOVEMENTS, BUT RESTLESS MOVEMENTS NOT NECESSARILY OBSERVED. LITTLE/NO DISTRESS. MODERATE AKATHISIA. AWAREOF RESTLESSNESS AS DESCRIBED FOR MILD AKATHISIA ABOVE, COMBINED WITH CHARACTERISTIC RESTLESS MOVEMENTS SUCH AS ROCKING FROM FOOT TO FOOT WHEN STANDING. CONDITION DISTRESSING MARKED AKATHISIA. RESTLESSNESS INCLUDES A COMPULSIVE DESIRE TO WALK OR PACE. HOWEVER, THE PATIENT IS ABLE TO REMAIN SEATED FOR AT LEAST FIVE MINUTES. THE CONDITION IS OBVIOUSLY DISTRESSING. SEVERE AKATHISIA. A STRONG COMPULSION TO PACE UP AND DOWN MOST OF THE TIME. UNABLE TO SIT OR LIE DOWN FOR MORE THAN A FEW MINUTES. CONSTANT RESTLESSNESS ASSOCIATED WITH INTENSE DISTRESS AND INSOMNIA Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 9
10 CDISC SDTM Questionnaire Supplement (Version 0.1) 5 Original and QSORRES Comparison 01-Objective (Original) NORMAL, OCCASIONAL FIDGETY MOVEMENTS OF THE LIMBS PRESENCE OF CHARACTERISTIC RESTLESS MOVEMENTS: SHUFFLING OR TRAMPING MOVEMENTS OF THE LEGS/FEET, OR SWINGING OF ONE LEG WHILE SITTING, AND/OR ROCKING FROM FOOT TO FOOT OR WALKING ON THE SPOT WHEN STANDING, BUT MOVEMENTS PRESENT FOR LESS THAN HALF THE TIME OBSERVED QSORRES Value NORMAL, OCCASIONAL FIDGETY MOVEMENTS OF THE LIMBS RESTLESS MOVEMENTS: SHUFFLING OR TRAMPING MOVEMENTS. SWINGING OF ONE LEG WHILE SITTING, AND/OR ROCKING FROM FOOT TO FOOT OR WALKING ON THE SPOT WHEN STANDING, PRESENT FOR LESS THAN HALF THE TIME OBSERVED PHENOMENA, AS DESCRIBED IN (1) ABOVE, WHICH ARE PRESENT FOR AT LEAST HALF THE OBSERVATION PERIOD PATIENT IS CONSTANTLY ENGAGED IN CHARACTERISTIC RESTLESS MOVEMENTS, AND/OR HAS THE INABILITY TO REMAIN SEATED OR STANDING WITHOUT WALKING OR PACING, DURING THE TIME OBSERVED Awareness (Original) ABSENCE OF INNER RESTLESSNESS NON-SPECIFIC SENSE OF INNER RESTLESSNESS THE PATIENT IS AWARE OF AN INABILITY TO KEEP THE LEGS STILL, OR A DESIRE TO MOVE THE LEGS, AND/OR COMPLAINS OF INNER RESTLESSNESS AGGRAVATED SPECIFICALLY BY BEING REQUIRED TO STAND STILL AWARENESS OF INTENSE COMPULSION TO MOVE MOST OF THE TIME AND/OR REPORTS STRONG DESIRE TO WALK OR PACE MOST OF THE TIME Distress (Original) NO DISTRESS MILD MODERATE SEVERE OBSERVED PHENOMENA, AS DESCRIBED IN (1) ABOVE, WHICH ARE PRESENT FOR AT LEAST HALF THE OBSERVATION PERIOD PATIENT IS CONSTANTLY ENGAGED IN CHARACTERISTIC RESTLESS MOVEMENTS, AND/OR HAS THE INABILITY TO REMAIN SEATED OR STANDING WITHOUT WALKING OR PACING, DURING THE TIME OBSERVED QSORRES Value ABSENCE OF INNER RESTLESSNESS NON-SPECIFIC SENSE OF INNER RESTLESSNESS THE PATIENT IS AWARE OF AN INABILITY TO KEEP THE LEGS STILL, OR A DESIRE TO MOVE THE LEGS, AND/OR COMPLAINS OF INNER RESTLESSNESS AGGRAVATED SPECIFICALLY BY BEING REQUIRED TO STAND STILL AWARENESS OF INTENSE COMPULSION TO MOVE MOST OF THE TIME AND/OR REPORTS STRONG DESIRE TO WALK OR PACE MOST OF THE TIME QSORRES Value NO DISTRESS MILD MODERATE SEVERE 2013 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 10
11 CDISC SDTM Questionnaire Supplement (Version 0.1) 01-Global Clinical Assessment ABSENT. NO EVIDENCE OF AWARENESS OF RESTLESSNESS. OBSERVATION OF CHARACTERISTIC MOVEMENTS OF AKATHISIA IN THE ABSENCE OF A SUBJECTIVE REPORT OF INNER RESTLESSNESS OR COMPULSIVE DESIRE TO MOVE THE LEGS SHOULD BE CLASSIFIED AS PSEUDOAKATHISIA QSORRES Value ABSENT. NO EVIDENCE OF AWARENESS OF RESTLESSNESS. MOVEMENTS OF AKATHISIA IN THE ABSENCE OF INNER RESTLESSNESS OR COMPULSIVE DESIRE TO MOVE THE LEGS SHOULD BE CLASSIFIED AS PSEUDOAKATHISIA QUESTIONABLE. NON-SPECIFIC INNER TENSION AND FIDGETY MOVEMENTS MILD AKATHISIA. AWARENESS OF RESTLESSNESS IN THE LEGS AND/OR INNER RESTLESSNESS WORSE WHEN REQUIRED TO STAND STILL. FIDGETY MOVEMENTS PRESENT, BUT CHARACTERISTIC RESTLESS MOVEMENTS OF AKATHISIA NOT NECESSARILY OBSERVED. CONDITION CAUSES LITTLE OR NO DISTRESS. QUESTIONABLE. NON-SPECIFIC INNER TENSION AND FIDGETY MOVEMENTS MILD AKATHISIA. AWARE OF RESTLESSNESS IN THE LEGS AND/OR INNER RESTLESSNESS WORSE WHEN REQUIRED TO STAND STILL. FIDGETY MOVEMENTS, BUT RESTLESS MOVEMENTS NOT NECESSARILY OBSERVED. LITTLE/NO DISTRESS. MODERATE AKATHISIA. AWARENESS OF RESTLESSNESS AS DESCRIBED FOR MILD AKATHISIA ABOVE, COMBINED WITH CHARACTERISTIC RESTLESS MOVEMENTS SUCH AS ROCKING FROM FOOT TO FOOT WHEN STANDING. PATIENT FINDS THE CONDITION DISTRESSING MARKED AKATHISIA. SUBJECTIVE EXPERIENCE OF RESTLESSNESS INCLUDES A COMPULSIVE DESIRE TO WALK OR PACE. HOWEVER, THE PATIENT IS ABLE TO REMAIN SEATED FOR AT LEAST FIVE MINUTES. THE CONDITION IS OBVIOUSLY DISTRESSING. SEVERE AKATHISIA. THE PATIENT REPORTS A STRONG COMPULSION TO PACE UP AND DOWN MOST OF THE TIME. UNABLE TO SIT OR LIE DOWN FOR MORE THAN A FEW MINUTES. CONSTANT RESTLESSNESS WHICH IS ASSOCIATED WITH INTENSE DISTRESS AND INSOMNIA. MODERATE AKATHISIA. AWAREOF RESTLESSNESS AS DESCRIBED FOR MILD AKATHISIA ABOVE, COMBINED WITH CHARACTERISTIC RESTLESS MOVEMENTS SUCH AS ROCKING FROM FOOT TO FOOT WHEN STANDING. CONDITION DISTRESSING MARKED AKATHISIA. RESTLESSNESS INCLUDES A COMPULSIVE DESIRE TO WALK OR PACE. HOWEVER, THE PATIENT IS ABLE TO REMAIN SEATED FOR AT LEAST FIVE MINUTES. THE CONDITION IS OBVIOUSLY DISTRESSING. SEVERE AKATHISIA. A STRONG COMPULSION TO PACE UP AND DOWN MOST OF THE TIME. UNABLE TO SIT OR LIE DOWN FOR MORE THAN A FEW MINUTES. CONSTANT RESTLESSNESS ASSOCIATED WITH INTENSE DISTRESS AND INSOMNIA. End of Document 2013 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 11
Modified Hachinski Ischemic Scale: NACC Version (MHIS-NACC) v.1.0
Modified Hachinski Ischemic Scale: NACC Version (MHIS-NACC) v.1.0 Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CAMD AD v2.0 Team
More informationBrief Psychiatric Rating Scale-Anchored (BPRS-A)
Brief Psychiatric Rating Scale-Anchored (BPRS-A) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaire Sub-team Notes
More informationBrief Psychiatric Rating Scale-Anchored (BPRS-A)
Brief Psychiatric Rating Scale-Anchored (BPRS-A) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaire Sub-team Notes
More informationEpworth Sleepiness Scale (ESS)
Epworth Sleepiness Scale (ESS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC Questionnaires Sub-team Notes to Readers This
More informationHospital Anxiety and Depression Scale (HADS)
Hospital Anxiety and Depression Scale (HADS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by Business & Decision Life Sciences and
More informationClinical Global Impression (CGI)
Clinical Global Impression (CGI) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,
More informationDisability Assessment for Dementia (DAD)
Disability Assessment for Dementia (DAD) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CAMD AD v1.1 Team and the CDISC Questionnaire
More informationMichigan Neuropathy Screening Instrument (MNSI)
Michigan Neuropathy Screening Instrument () Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,
More informationNeuropathic Pain Scale (NPS)
Neuropathic Pain Scale (NPS) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by Business & Decision Life Sciences and the CDISC Questionnaire
More informationHamilton Depression Rating Scale 17-Item (HAMD 17)
Hamilton Depression Rating Scale -Item ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,
More informationColumbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE)
Columbia-Suicide Severity Rating Scale Baseline ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial
More informationColumbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE)
Columbia-Suicide Severity Rating Scale Baseline ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial
More informationColumbia-Suicide Severity Rating Scale Baseline (C-SSRS BASELINE)
Columbia-Suicide Severity Rating Scale Baseline ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial
More informationShort-Form McGill Pain Questionniare-2 (SHORT-FORM MPQ-2)
Short-Form McGill Pain Questionniare-2 ( ) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations,
More informationTimed Up and Go (TUG)
Timed Up and Go (TUG) Functional Test Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by Multiple Sclerosis Outcomes Assessment Consortium and the
More informationPain Relief (PR) Notes to Readers
Pain (PR) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations, Innovations, Opportunities,
More informationUnified Parkinson's Disease Rating Scale UPDRS
Unified Parkinson's Disease Rating Scale Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and National Institute of Neurological
More informationUnified Parkinson's Disease Rating Scale UPDRS
Unified Parkinson's Disease Rating Scale Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and National Institute of Neurological
More informationLet s Create Standard Value Level Metadata
PRA Health Sciences PhUSE US Connect 2019 Paper DS12 February 27, 2019 David Fielding Value Level Metadata Value Level Metadata is an important part of the Define-XML that allows us to explain our study
More informationPharmaSUG Paper DS12
PharmaSUG 2017 - Paper DS12 Considerations and Conventions in the Submission of the SDTM Tumor and Response Domains Jerry Salyers, Accenture Accelerated R&D Services, Berwyn, PA Fred Wood, Accenture Accelerated
More informationCDISC BrCa TAUG & Oncology Information Session
1 15 September 2016 CDISC BrCa TAUG & Oncology Information Session Barrie Nelson @ DCDISC 2 24 February 2016 10:00-11:30am CST CDISC Oncology Information Session Rhonda Facile, Ann White, John Owen, Diane
More informationAlzheimer s Disease-specific Therapeutic Area Supplement to the Study Data Tabulation Model User Guide
CDISC Alzheimer s disease SDTM User Guide (Version 1.0) Alzheimer s Disease-specific Therapeutic Area Supplement to the Study Data Tabulation Model User Guide Prepared by the Coalition Against Major Diseases
More informationIntervention ML: Mapping of Meal data. Rahul Loharkar, inventiv Health Clinical, Pune, India Sandeep Sawant, inventiv Health Clinical, Mumbai, India
Paper DS06 Intervention ML: Mapping of Meal data. Rahul Loharkar, inventiv Health Clinical, Pune, India Sandeep Sawant, inventiv Health Clinical, Mumbai, India ABSTRACT The focus of most bioavailability/bioequivalence
More informationProject Charter. Template v2 June 3, February 25, Name of Project: Prostate Cancer (PrCa) Therapeutic Area Data Standards
Project Charter Template v2 June 3, 2015 Name of Project: Prostate Cancer (PrCa) Therapeutic Area Data Standards February 25, 2016 Project Manager: John Owen 1. Scope of Prostate Cancer Therapeutic Area
More informationA Rating Scale for Drug-Induced Akathisia
British Journal of Psychiatry (1989), 154, 672â 676 A Rating Scale for Drug-Induced Akathisia THOMAS R. E. BARNES A ratingscalefordrug-inducedakathisiahas been derivedthatincorporatesdiagnosticriteria
More informationJerry Salyers, Accenture Accelerated R&D Services Fred Wood, Accenture Accelerated R&D Services. PhUSE 2017 Edinburgh, Scotland Paper #DS05
Jerry Salyers, Accenture Accelerated R&D Services Fred Wood, Accenture Accelerated R&D Services PhUSE 2017 Paper #DS05 } Review of Tumor domains and representative CRFs Ø TU (Tumor Identification) Ø TR
More informationHow to manage changes to CDISC standards at Novo Nordisk. PhUSE EU Connect 2018 Sune Dandanell and Mikkel Traun
How to manage changes to CDISC standards at Novo Nordisk PhUSE EU Connect 2018 Sune Dandanell and Mikkel Traun How to manage changes to CDISC standards at Novo Nordisk 06-Nov-2018 2 How to manage changes
More informationTherapeutic Area User Guide Cardiovascular V1.0 Public Review Webinar April 3, 2014
Therapeutic Area User Guide Cardiovascular V1.0 Public Review Webinar April 3, 2014 1 Therapeutic Area User Guide CV V1.0 Public Review Webinar April 3, 2014 James Tcheng, MD, FACC, DCRI Steve Kopko, CDISC,
More informationCFAST Asthma Project. Rhonda Facile. CDISC International Interchange Session 4B: Therapeutic Area Standards in Action November 6, 2013
CFAST Asthma Project Rhonda Facile CDISC International Interchange Session 4B: Therapeutic Area Standards in Action November 6, 2013 1 Asthma Project CFAST Development Principles Asthma Background What
More informationCDISC - Mapping New Pathways for Novartis. Darren Weston, Project Leader Pat Majcher, Senior Principal Programmer
CDISC - Mapping New Pathways for Novartis Darren Weston, Project Leader Pat Majcher, Senior Principal Programmer Shuhong hong Xie, Senior Statistical Programmer Agenda What was the submission request?
More informationExamples: Tables. Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients
Examples: Tables Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients Descriptive Statistics Table 1. Body Mass Index using Last Observation Carried
More informationDesign and Construct Efficacy Analysis Datasets in Late Phase Oncology Studies
PharmaSUG China Design and Construct Efficacy Analysis s in Late Phase Oncology Studies Huadan Li, MSD R&D (China) Co., Ltd., Beijing, China Changhong Shi, MSD R&D (China) Co., Ltd., Beijing, China ABSTRACT
More informationIAASB Main Agenda (March 2005) Page Agenda Item. DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005
IAASB Main Agenda (March 2005) Page 2005 579 Agenda Item 13-F DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005 Introduction This memorandum provides some background to, and
More informationPharmaSUG Paper DS04
PharmaSUG2014 - Paper DS04 Considerations in the Submission of Exposure Data in SDTM-Based Datasets Fred Wood, Accenture Life Sciences, Wayne, PA Jerry Salyers, Accenture Life Sciences, Wayne, PA Richard
More informationADaM Considerations and Content in the TA User Guides. Susan J Kenny, PhD Maximum Likelihood, Inc.
ADaM Considerations and Content in the TA User Guides Susan J Kenny, PhD Maximum Likelihood, Inc. Topics to Discuss Focus of ADaM content Overview of TAUGs with ADaM content Specific ADaM content in selected
More informationThe Standard for the Exchange of Nonclinical Data (SEND): History, Basics, and Comparisons with Clinical Data
Life Sciences Accelerated R&D Services The Science of Getting Products to Patients Faster The Standard for the Exchange of Nonclinical Data (SEND): History, Basics, and Comparisons with Clinical Data Fred
More informationPharmaSUG 2018 Paper AD-02
PharmaSUG 2018 Paper AD-02 Derivations of Response Status from SDTM Domains using RECIST 1.1 Christine Teng, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ USA Pang Lei, Merck Research Laboratories,
More informationQuality ID #168 (NQF 0115): Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration National Quality Strategy Domain: Effective Clinical Care
Quality ID #168 (NQF 0115): Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More information2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #428: Pelvic Organ Prolapse: Preoperative Assessment of Occult Stress Urinary Incontinence National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More information2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #109: Osteoarthritis (OA): Function and Pain Assessment National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationSDTMIG v3.3 Batch 2 Upcoming Public Review. Presented by Fred Wood
1 SDTMIG v3.3 Batch 2 Upcoming Public Review Presented by Fred Wood 2 SDTMIG v3.3 Batch 2? What This package constitutes Batch 2 for the planned SDTMIG v3.3. It is planned to be available for a public
More informationDENOMINATOR: All patients undergoing anterior or apical pelvic organ prolapse (POP) surgery
Measure #428: Pelvic Organ Prolapse: Preoperative Assessment of Occult Stress Urinary Incontinence National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTY
More informationQuality ID #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care
Quality ID #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationMeasure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care
Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome
Quality ID #432: Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationRequest for Proposals
Background The U.S. Preventive Services Task Force (USPSTF or Task Force) is an independent, volunteer panel of national experts in prevention and evidence-based medicine. Since its inception in 1984,
More informationQuality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology
More informationMeasure #355: Unplanned Reoperation within the 30 Day Postoperative Period National Quality Strategy Domain: Patient Safety
Measure #355: Unplanned Reoperation within the 30 Day Postoperative Period National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:
More informationLeveraging Standards for Effective Visualization of Early Efficacy in Clinical Trial Oncology Studies
PharmaSUG 2018 - Paper DV-26 Leveraging Standards for Effective Visualization of Early Efficacy in Clinical Trial Oncology Studies Kelci Miclaus and Lili Li, JMP Life Sciences SAS Institute ABSTRACT Solid
More informationQuality ID #1 (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) National Quality Strategy Domain: Effective Clinical Care
Quality ID #1 (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:
More informationQuality ID #278: Sleep Apnea: Positive Airway Pressure Therapy Prescribed National Quality Strategy Domain: Effective Clinical Care
Quality ID #278: Sleep Apnea: Positive Airway Pressure Therapy Prescribed National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationCDISC Public Webinar- Post Traumatic Stress Disorder Therapeutic Area User Guide
CDISC Public Webinar- Post Traumatic Stress Disorder Therapeutic Area User Guide 26 September 2017 Allyson Gage Cohen Veterans Biosciences Amy Palmer CDISC Kathleen Mellars CDISC Dana Booth - CDISC 1 AGENDA
More informationPARKINSON S DISEASE MEDICAL ASSESSMENT FORM FOR SOCIAL SECURITY DISABILITY APPLICATION
PARKINSON S DISEASE MEDICAL ASSESSMENT FORM FOR SOCIAL SECURITY DISABILITY APPLICATION TO: RE: SSN: Dr: Please answer the following questions concerning your patient s Parkinson s disease and other impairments.
More informationQuality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care
Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage
More informationQuality ID #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care
Quality ID #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage
More informationMeasure #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care
Measure #178: Rheumatoid Arthritis (RA): Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: Percentage
More informationDESCRIPTION: Percentage of final reports for screening mammograms that are classified as probably benign
Measure #146 (NQF 0508): Radiology: Inappropriate Use of Probably Benign Assessment Category in Screening Mammograms National Quality Strategy Domain: Efficiency and Cost Reduction 2016 PQRS OPTIONS F
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency
Quality ID #322: Cardiac Stress Imaging t Meeting Appropriate Use Criteria: Preoperative Evaluation in Low-Risk Surgery Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS
More informationCDISC Controlled Terminology. Presented by Chris Gemma and Erin Muhlbradt, Ph.D.
CDISC Controlled Terminology Presented by Chris Gemma and Erin Muhlbradt, Ph.D. Panelists Erin Muhlbradt, Clincal/Biomedical Information Specialist, MSC Chris Gemma, Project Manager, CDISC 2 Question &
More informationDENOMINATOR: All patients undergoing anterior or apical pelvic organ prolapse (POP) surgery
Quality ID #434: Proportion of Patients Sustaining a Ureter Injury at the Time of Pelvic Organ Prolapse Repair National Quality Strategy Domain: Patient Safety Meaningful Measure Area: Preventable Healthcare
More informationREX REX Clinical Assessment Guide
REX Clinical Assessment Guide All product names and brand names in this document are trademarks or registered trademarks of their respective holders. Copyright Rex Bionics Ltd 2016. All rights reserved.
More informationDENOMINATOR: All patient visits for patients aged 21 years and older with a diagnosis of OA
Quality ID #109: Osteoarthritis (OA): Function and Pain Assessment National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationDENOMINATOR: All patients undergoing anterior or apical pelvic organ prolapse (POP) surgery
Quality ID #428: Pelvic Organ Prolapse: Preoperative Assessment of Occult Stress Urinary Incontinence National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationDESCRIPTION: Percentage of final reports for screening mammograms that are classified as probably benign
Quality ID #146 (NQF 0508): Radiology: Inappropriate Use of Probably Benign Assessment Category in Screening Mammograms National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS F INDIVIDUAL
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority
Quality ID #355: Unplanned Reoperation within the 30 Day Postoperative Period National Quality Strategy Domain: Patient Safety Meaningful Measure Area: Admissions and Readmissions to Hospitals 2019 COLLECTION
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #322: Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2016 PQRS
More informationQuality ID#164 (NQF 0129): Coronary Artery Bypass Graft (CABG): Prolonged Intubation National Quality Strategy Domain: Effective Clincial Care
Quality ID#164 (NQF 0129): Coronary Artery Bypass Graft (CABG): Prolonged Intubation National Quality Strategy Domain: Effective Clincial Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #422 (NQF 2063): Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury - National Quality Strategy Domain: Patient Safety 2018 OPTIONS
More informationClinical Review Report (Sample)
CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) GENERIC DRUG NAME (BRAND NAME) (Manufacturer) Indication: Text Disclaimer: The information in this document is intended to help Canadian health
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Transfer of Health Information and Interoperability 2019 COLLECTION TYPE:
More informationDisclaimer. The following report contains a description of the request, request specifications, and results from the modular program run(s).
Disclaimer The following report(s) provides findings from an FDA initiated query using its Mini Sentinel pilot. While Mini Sentinel queries may be undertaken to assess potential medical product safety
More informationResidual Functional Capacity Questionnaire PARKINSON S DISEASE
Residual Functional Capacity Questionnaire PARKINSON S DISEASE Patient: DOB: Physician completing this form: Please complete the following questions regarding this patient's impairments and attach all
More informationOPNAVINST G 30 Dec 05
Appendix 23-B Computer Workstation Checklist The computer workstation checklist is one method available for performing computer workstation assessments. The checklist is designed to be printed as two double-sided
More informationMeasure #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health
Measure #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationAnkle Sprain. Information for patients. This booklet provides information for patients with ankle sprain. Physiotherapy
Ankle Sprain Information for patients This booklet provides information for patients with ankle sprain. Physiotherapy Website http://www.mtw.nhs.uk/physiotherapy/ Telephone 01892 632902 / 01622 224308
More information2019 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA CMS Web Interface V3.0 Page 1 of 18 xx/xx/2018 Contents INTRODUCTION... 3 CMS WEB INTERFACE SAMPLING INFORMATION... 4
More informationMeasure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care
Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: All patients
More informationAdult ADHD-RS-IV* with Adult Prompts
Adult ADHD-RS-IV* with Adult Prompts The ADHD-RS-IV with Adult Prompts is an 8-item scale based on the DSM-IV-TR criteria for ADHD that provides a rating of the severity of symptoms. The adult prompts
More informationDENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis
Quality ID #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Preventive Care
More informationMeasure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology reports
More informationQuality ID #154 (NQF: 0101): Falls: Risk Assessment National Quality Strategy Domain: Patient Safety
Quality ID #154 (NQF: 0101): Falls: Risk Assessment National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage of
More informationStudy Endpoint Considerations: Final PRO Guidance and Beyond
Study Endpoint Considerations: Final PRO Guidance and Beyond Laurie Burke Associate Director for Study Endpoints and Labeling OND/CDER/FDA Presented at: FIRST ANNUAL PATIENT REPORTED OUTCOMES (PRO) CONSORTIUM
More informationCopyright American Psychological Association
Introduction Sleep is an essential part of life that most people take for granted. We assume that the mind and the body will naturally turn off when we decide to lie down in bed and rest. After about 8
More informationResidual Functional Capacity Questionnaire MULTIPLE SCLEROSIS
Residual Functional Capacity Questionnaire MULTIPLE SCLEROSIS Patient: DOB: Physician completing this form: Please complete the following questions regarding this patient's impairments and attach all supporting
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency
Quality ID #323: Cardiac Stress Imaging t Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI) National Quality Strategy Domain: Efficiency and Cost Reduction
More informationCDISC SHARE. CDISC Shared Health and Research Electronic Library Pilot Report. Date: 19 January 2010 Version: 1.0 CDISC, 2010
CDISC SHARE CDISC Shared Health and Research Electronic Library Pilot Report Date: 19 January 2010 Version: 1.0 CDISC, 2010 Page 1 of 28 Document History Issue Author Date Description 0.1 Pilot Team 9
More information4. Pertinent physical findings including: a. Results of tests performed on patient, including dates and specific findings:
Medical Assessment Form Patient: SSN: Please answer each of the following questions about the patient. They concern the patient s claim of entitlement to disability benefits under the Social Security Act.
More informationBreast Cancer TAUG Overview and Implementation
Breast Cancer TAUG Overview and Implementation Anita Umesh, Ph.D. Senior Scientist, Enterprise Informatics Illumina, Inc. Bay Area CDISC User Group 9 December 2015 2014 Illumina, Inc. All rights reserved.
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic Conditions 2019 COLLECTION
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #177: Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity National Quality Strategy Domain: Effective Clinical Care Measure Meaningful Measure Area: Management of Chronic Conditions
More informationQuality ID #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health
Quality ID #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationQuality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care
Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process-High Priority
Quality ID #463: Prevention of Post-Operative Vomiting (POV) Combination Therapy (Pediatrics) National Quality Strategy Domain: Patient Safety Meaningful Measure Area: Preventive Care 2019 COLLECTION TYPE:
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #185 (NQF 0659): Colonoscopy Interval for Patients with a History of Adenomatous Polyps Avoidance of Inappropriate Use National Quality Strategy Domain: Communication and Care Coordination 2018
More informationDENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period
Measure #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR
More informationCLASSIFICATION AND TREATMENT PLANS
CLASSIFICATION AND TREATMENT PLANS C H A P T E R 2 EXPERIENCES OF CLIENT AND CLINICIAN PSYCHOLOGICAL DISORDER: EXPERIENCES OF CLIENT AND CLINICIAN Psychologist: Healthcare professional offering psychological
More informationDENOMINATOR: All patients 18 and older prescribed opiates for longer than six weeks duration
Quality ID #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Prevention and Treatment of Opioid and Substance Use
More informationModular Program Report
Disclaimer The following report(s) provides findings from an FDA initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also
More informationQuality ID #155 (NQF: 0101): Falls: Plan of Care National Quality Strategy Domain: Communication and Care Coordination
Quality ID #155 (NQF: 0101): Falls: Plan of Care National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
More informationDementia Friendly Communities Recognition Process. Karishma Chandaria Dementia Friendly Communities Programme Manager
Dementia Friendly Communities Recognition Process Karishma Chandaria Dementia Friendly Communities Programme Manager Living well with dementia Development of DFCs Progress in creating dementia friendly
More information